Biotech crossover investor Foresite is lining up a $650M stake for the big gambles to come
Biotech investor Foresite Capital is lining up a new fund, and this time it’s going big.
In a new SEC filing posted Thursday, Foresite alerted the industry that it is lining up a $650 million successor to the $450 million Fund III that got started two years ago.
Foresite is a very familiar if fairly low-key player in the biotech world; a crossover investor that has kept friendly ties in place with syndicates that often include cagey players like RA Capital, which enjoys nothing as much as looking for some fast returns — say a year out — through go-go markets.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.